Comparison of Rivaroxaban Versus Warfarin in Resolution of Left Ventricular Thrombus After Acute Anterior Wall Myocardial Infarction: A Prospective Cohort Study
Rivaroxaban vs Warfarin for Left Ventricular Thrombus
DOI:
https://doi.org/10.54393/pjhs.v7i6.3638Keywords:
Echocardiography, Myocardial Infarction, Rivaroxaban, Thrombosis, WarfarinAbstract
There is emerging evidence that direct oral anticoagulants like rivaroxaban are a more effective alternative for thrombus resolution after acute myocardial infarction. Objective: To compare the rate of left ventricular thrombus resolution between rivaroxaban and warfarin after acute anterior wall myocardial infarction. Methods: This prospective cohort study was conducted in the Department of Cardiology at Sheikh Zayed Hospital, Rahim Yar Khan, from May to November 2025. A total of 290 participants with left ventricular thrombus after acute anterior wall myocardial infarction were enrolled in the study. The unexposed group consisted of patients treated with warfarin, with the dose adjusted to maintain an INR of 2.0-3.0. The exposed group received rivaroxaban (20 mg daily; 15 mg if creatinine clearance was 30–50 ml/min/1.73m2). Echocardiography was performed at baseline and repeated after three months to assess thrombus resolution. Data were analyzed through SPSS version 25.0. Descriptive statistics were run, and an independent sample t-test was used for numerical comparison and a chi-square test for categorical comparison. Results: The mean age was 60.4 ± 6.4 years, with 73.4% males. Baseline demographics were comparable between the groups. Thrombus resolution at three months was achieved in 52.4% overall, significantly higher in rivaroxaban versus warfarin (61.4% vs. 43.4%, p-value=0.002; RR: 1.4, 95% CI: 1.1–1.8). Diabetes, hypertension, and thrombus size ≥1 cm were associated with lower thrombus resolution rates. Conclusions: Rivaroxaban demonstrated better efficacy over warfarin for thrombus resolution in post-myocardial infarction patients. Comorbid diabetes, hypertension, and larger thrombosis size were significant negative predictors of resolution.
References
Camaj A, Fuster V, Giustino G, Bienstock SW, Sternheim D, Mehran R et al. Left Ventricular Thrombus Following Acute Myocardial Infarction: JACC State-Of-The-Art Review. Journal of the American College of Cardiology. 2022 Mar; 79(10): 1010-1022. doi: 10.1016/j.jacc.2022.01.011. DOI: https://doi.org/10.1016/j.jacc.2022.01.011
Jones DA, Wright P, Alizadeh MA, Fhadil S, Rathod KS, Guttmann O et al. The Use of Novel Oral Anticoagulants Compared to Vitamin K Antagonists (Warfarin) in Patients with Left Ventricular Thrombus After Acute Myocardial Infarction. European Heart Journal-Cardiovascular Pharmacotherapy. 2021 Sep; 7(5): 398-404. doi: 10.1093/ehjcvp/pvaa096. DOI: https://doi.org/10.1093/ehjcvp/pvaa096
Zhou X, Shi R, Wu G, Zhu Q, Zhou C, Wang L, Xue C, Jiang Y, Cai X, Huang W, Shan P. The prevalence, predictors, and outcomes of spontaneous echocardiographic contrast or left ventricular thrombus in patients with HFrEF. European Society of Cardiology heart failure. 2021 Apr; 8(2): 1284-1294. doi: 10.1002/ehf2.13196. DOI: https://doi.org/10.1002/ehf2.13196
Alcalai R, Butnaru A, Moravsky G, Yagel O, Rashad R, Ibrahimli M et al. Apixaban vs. Warfarin in Patients with Left Ventricular Thrombus: A Prospective Multicentre Randomized Clinical Trial. European Heart Journal-Cardiovascular Pharmacotherapy. 2022 Nov; 8(7): 660-667. doi: 10.1093/ehjcvp/pvab057. DOI: https://doi.org/10.1093/ehjcvp/pvab057
Berkowitz SD, Bauersachs RM, Szarek M, Nehler MR, Debus ES, Patel MR et al. Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis. 2022 May 1;20(5):1193-205. doi: 10.1111/jth.15673. DOI: https://doi.org/10.1111/jth.15673
Camanho LE and Santos GV. Rivaroxaban: Does it Really Need to Monitor its Anticoagulant Effect in Clinical Practice? International Journal of Cardiovascular Sciences. 2021 Mar; 34(2): 122-123. doi: 10.36660/ijcs.20200373. DOI: https://doi.org/10.36660/ijcs.20200373
Zhang Z, Si D, Zhang Q, Qu M, Yu M, Jiang Z et al. Rivaroxaban Versus Vitamin K Antagonists (Warfarin) Based on the Triple Therapy for Left Ventricular Thrombus After ST-Elevation Myocardial Infarction. Heart and Vessels. 2022 Mar; 37(3): 374-384. doi: 10.1007/s00380-021-01921-z. DOI: https://doi.org/10.1007/s00380-021-01921-z
Mir T, Sattar Y, Attique HB, Hussain T, Alraies MC, Sheikh M et al. Meta-analysis of Direct Oral Anticoagulants Compared with Vitamin K Antagonist for Left Ventricular Thrombus. Cardiovascular Revascularization Medicine. 2022 Feb; 35: 141-146. doi: 10.1016/j.carrev.2021.03.001. DOI: https://doi.org/10.1016/j.carrev.2021.03.001
Mansouri P, Jazi ZA, Mansouri MH, Dehghan H, Zavar R, Hashemi SM et al. Evaluation of the Efficacy and Safety of Rivaroxaban Compared to Warfarin in Patients with Left Ventricular Apical Thrombus: A Randomized Clinical Trial. Thrombosis Journal. 2024 Jul; 22(1): 66. doi: 10.1186/s12959-024-00632-5. DOI: https://doi.org/10.1186/s12959-024-00632-5
Prajapati D. Comparison of Warfarin Versus Rivaroxaban in Management of Post-Myocardial Infarction Left Ventricular Thrombus in a Tertiary Cardiac Centre of Nepal: A Randomized Controlled Study. 2024 Nov: 1-32.
Levine GN, McEvoy JW, Fang JC, Ibeh C, McCarthy CP, Misra A et al. Management of Patients at Risk for and with Left Ventricular Thrombus: A Scientific Statement from the American Heart Association. Circulation. 2022 Oct; 146(15): 205-223. doi: 10.1161/CIR.0000000000001092. DOI: https://doi.org/10.1161/CIR.0000000000001092
Olie RH, Winckers K, Rocca B, Ten Cate H. Oral Anticoagulants Beyond Warfarin. Annual Review of Pharmacology and Toxicology. 2024 Jan; 64(1): 551-575. doi: 10.1146/annurev-pharmtox-032823-122811. DOI: https://doi.org/10.1146/annurev-pharmtox-032823-122811
Jenab Y, Sadeghipour P, Mohseni-Badalabadi R, Kaviani R, Hosseini K, Pasebani Y et al. Direct Oral Anticoagulants or Warfarin in Patients with Left Ventricular Thrombus After ST-Elevation Myocardial Infarction: A Pilot Trial and a Prespecified Meta-Analysis of Randomised Trials. Euro Intervention. 2025 Jan; 21(1): 82. doi: 10.4244/EIJ-D-24-00527. DOI: https://doi.org/10.4244/EIJ-D-24-00527
Shrestha DB, Dawadi S, Dhakal B, Shtembari J, Patel T, Shaikh R et al. Direct Oral Anticoagulants Versus Vitamin K Antagonist in Left Ventricular Thrombus: An Updated Meta‐Analysis. Health Science Reports. 2023 Nov; 6(11): 1736. doi: 10.1002/hsr2.1736. DOI: https://doi.org/10.1002/hsr2.1736
Attachaipanich T, Thanyaratsarun T, Attachaipanich S, Danpanichkul P, Kaewboot K. Efficacy of Direct Oral Anticoagulants Vs. Warfarin in Left Ventricular Thrombus in Myocardial Infarction: Systematic Review and Meta-Analysis. Journal of Cardiovascular Medicine. 2025 Jan; 26(1): 40-49. doi: 10.2459/JCM.0000000000001683. DOI: https://doi.org/10.2459/JCM.0000000000001683
Jiang H, Jiang Y, Ma H, Zeng H, Lv J. Effects of Rivaroxaban and Warfarin on the Risk of Gastrointestinal Bleeding and Intracranial Hemorrhage in Patients with Atrial Fibrillation: Systematic Review and Meta‐Analysis. Clinical Cardiology. 2021 Sep; 44(9): 1208-1215. doi: 10.1002/clc. 23690. DOI: https://doi.org/10.1002/clc.23690
Yang Q, Quan X, Wang C, Yu L, Yang Y, Zhu J et al. A Prediction Model for Left Ventricular Thrombus Persistence/Recurrence: Based on a Prospective Study and a Retrospective Study. Thrombosis Journal. 2023 May; 21(1): 50. doi: 10.1186/s12959-023-00488-1. DOI: https://doi.org/10.1186/s12959-023-00488-1
Lu Z, Song B, Liu X, Zhang N, Li F, Xu F et al. Factors Predicting Resolution of Left Ventricular Thrombus in Different Time Windows After Myocardial Infarction. BioMed Central Cardiovascular Disorders. 2024 May; 24(1): 278. doi: 10.1186/s12872-024-03898-9. DOI: https://doi.org/10.1186/s12872-024-03898-9
Kim SE, Lee CJ, Oh J, Kang SM. Factors Influencing Left Ventricular Thrombus Resolution and Its Significance on Clinical Outcomes. European Society of Cardiology heart failure. 2023 Jun; 10(3): 1987-1995. doi: 10.1002/ehf2.14369. DOI: https://doi.org/10.1002/ehf2.14369
Ahmed HS, Ede H, Mahfouz AS, Rahhal AA, Ali MA, Issa AF et al. Surrogates of the Left Ventricular Thrombus Resolution: A Retrospective Data Review. Türk Kardiyoloji Derneği Arşivi. 2022 Apr; 50(3): 168. doi: 10.5543/tkda.2022.21068. DOI: https://doi.org/10.5543/tkda.2022.21068
Shi B, Zhang R, Song C, Cui K, Zhang D, Jia L et al. Impacts of Diabetes Mellitus on Cardiovascular Outcomes and Differential Effects of Direct Oral Anticoagulants in Patients with Left Ventricular Thrombus. Reviews in Cardiovascular Medicine. 2023 Feb; 24(3): 65. doi: 10.31083/j. rcm2403065. DOI: https://doi.org/10.31083/j.rcm2403065
Vaidya AR, Wolska N, Vara D, Mailer RK, Schröder K, Pula G. Diabetes and Thrombosis: A Central Role for Vascular Oxidative Stress. Antioxidants. 2021 Apr; 10(5): 706. doi: 10.3390/antiox10050706. DOI: https://doi.org/10.3390/antiox10050706
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
